A common question facing management teams, boards and business developers is to define the value of their assets. While complex to answer, those who have been in this situation knows that a deal negotiation or securing an investment requires a credible and well-founded answer for the discussion to progress. In fact, any transaction such as M&As, licensing, fundraising or IPOs is likely to require a financial justification. Biotech valuation is not like other industries though, which is why we are now launching tailored courses in valuation drawing upon on our experience and knowledge in this specialized field.
Not only does biotech valuation require financial modelling skills, but also the comprehensive understanding of fundamentals in drug development due to the regulatory complexity and high knowledge hurdle. Our aim with the Biotech Valuation courses is therefore to empower biotech professionals with the tools and methods to quantify and verify key assumptions about a project whether you are sitting on the selling or the buying end of a transaction. Diligent preparation and a profound understanding of how each of these dimensions affect your company or asset value will make you a strong negotiator.
The Biotech Valuation courses is part of our new initiative MSC Academy and is our way of sharing our passion for life sciences with as many as possible. C-suites, leaders, students – anyone sharing our interest in the Nordic biotech space – we are excited to be working together to drive the future of medicine.
The goal has been to create something actionable for CEOs, business developers, board members and investors in small biotech companies to use when preparing negotiations for financing rounds or business deals.
The content of our courses draws from the abundant experience we have in biotech valuation across most indication categories, many rare diseases, small molecules, biologics, cell and gene therapies as well as various platform technologies.
The goal has been to create something actionable for CEOs, business developers, board members and investors in small biotech companies to use when preparing negotiations for financing rounds or business deals. That is why the courses also have an element of interactive sessions with discussions, benchmarks, working in simpler valuation models and the content laid out in a book.
We offer both a fundamentals and advanced course; thus, have offerings for both biotech executives who are new to building valuation models as well as professionals with more experience.